Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.
The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.
Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.
Hercules Capital has replaced its existing $200 million credit facility with MUFG Union Bank with a new $400 million credit facility.
Urovant Sciences has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma, a global Japanese pharmaceutical company.
Antares Pharma amended its credit facility with Hercules Capital, to increase the available debt capital by $25 million for a term loan of up to $50 million.
Hercules Capital promoted R. Bryan Jadot to head of Life Sciences Venture Lending and Steve Kuo to head of Technology Venture Lending.